Southern Research scientists are investigating how the Zika virus is able to find a safe harbor in an infected host’s tissue and stage a rebound weeks after the virus was…
One year after the Zika virus was first confirmed in Latin America, the response from the global scientific community has been resolute, and Southern Research has been there every step of the way.
Experts in our Drug Discovery and Drug Development divisions are working with a sense of urgency to establish the pipelines needed to support research on the fundamental questions behind the virus.
With unique in vitro models and Nonhuman Primate (NHP) and GLP capabilities, our infectious disease research team is fully prepared to add significant value to the development of prophylactic and therapeutic strategies against Zika.
Current capabilities and available services include: